Below From a report released a couple of days ago. Seems maybe the WHO is not aware of the progress of rce 327. I wonder what is involved in bringing it to their attention. This might be a question for the company as the WHO appear to be showing great interest in "43 antibiotics currently in clinical development" and appear frustrated that many still do not address the most dangerous.
surely the quote below shows the significance of what rce are claiming to be able to do?
"that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world’s most dangerous bacteria."
Not sure if I'm missing something but I thought recce previously claimed they had effect against a large number of the most dangerous pathogens/bacteria listed by the WHO and the only ones they hadn't killed were ones they weren't allowed access to for testing?? If that were the case surely it would benefit us if who knew this? It shows the global potential if this works.
The world is still failing to develop desperately needed antibacterial treatments, despite growing awareness of the urgent threat of antibiotic resistance, according to report by the World Health Organization. WHO reveals that none of the 43 antibiotics that are currently in clinical development sufficiently address the problem of drug resistance in the world’s most dangerous bacteria.“The persistent failure to develop, manufacture, and distribute effective new antibiotics is further fueling the impact of antimicrobial resistance (AMR) and threatens our ability to successfully treat bacterial infections,” says Dr. Hanan Balkhy, WHO Assistant Director General on AMR.Almost all the new antibiotics that have been brought to market in recent decades are variations of antibiotic drugs classes that had been discovered by the 1980s.The impact of AMR is most severe in resource-constrained settings and among vulnerable groups such as new-borns and young children. Bacterial pneumonia and bloodstream infections are among the major causes of childhood mortality under the age of 5. Approximately 30% of neonates with sepsis die due to bacterial infections resistant to multiple first-line antibiotics.
RCE Price at posting:
$1.27 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)